GlobeNewswire PharmaOriginal article
Actimed Therapeutics Reacquires Global Rights to S-oxprenolol, Broadening Pipeline Opportunity
PartnershipS-oxprenololPositive
AI Analysis
Summary
Actimed Therapeutics reacquired exclusive global rights to S-oxprenolol, an anabolic-catabolic transforming agent, from Faraday Pharmaceuticals, broadening its pipeline for cancer cachexia and muscle wasting treatments.
Outcome Details
Reacquisition of exclusive global rights
Importance:5/10
Sentiment:
0.60
asset reacquisitionpipeline expansionexclusive rightsmuscle wastingcancer cachexia
Related Companies
Read the original article
Published by GlobeNewswire Pharma on August 6, 2026 7:00 AM